Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Wound Repair Regen ; 28(2): 177-184, 2020 03.
Article in English | MEDLINE | ID: mdl-31667902

ABSTRACT

The purpose of this study was to investigate the effect of the peptide analgesic hybrid compounds: AWL3106 analog of dermorphin and substance P (7-11), and biphalin enkephalin analog on wound healing in streptozotocin-induced diabetic rats. The diabetes was induced in 6-7 week-old male Wistar rats by intraperitoneal injection of streptozotocin. After 70 days, the wounds were created on the back of the rats and then, once a day for 21 days, the dressing containing lanolin ointment, 10% of keratin scaffolds, and 1 mM of AWL3106 or biphalin was applied. The wounds histology were analyzed by hematoxylin and eosin staining. The orientation and organization of collagen was analyzed by Masson's trichome staining. The number of macrophages, blood vessels, and fibroblasts were visualized by CD68, CD34, and vimentin immunoreactivity, respectively. Our results demonstrated that the wound area of AWL3106- and biphalin-treated groups was greatly reduced (up to 47% on the 7 day) in comparison with untreated diabetic groups. The immunohistochemical staining of macrophages demonstrated that AWL3106 and biphalin accelerated inflammatory progression and subsequently decreased persistent inflammation. The histological analysis showed that the structure of tissue in the groups under the study was very similar to the one of wound tissue in N-DM group. The H&E and Masson's trichome staining demonstrated that the orientation and organization of collagen as well as the number and shape of blood vessels were better in 3106- and BIF-treated group than in DM group. In conclusion, the obtained data suggested that our hybrid peptides enhanced wound healing, particularly by accelerating the inflammatory phase and promoted the wound closure.


Subject(s)
Analgesics/pharmacology , Diabetes Mellitus, Experimental , Enkephalins/pharmacology , Macrophages/drug effects , Neovascularization, Physiologic/drug effects , Opioid Peptides/pharmacology , Peptide Fragments/pharmacology , Substance P/pharmacology , Wound Healing/drug effects , Animals , Collagen/drug effects , Collagen/metabolism , Epidermal Cells/drug effects , Fibroblasts/drug effects , Male , Rats , Rats, Wistar
2.
PLoS One ; 12(8): e0184034, 2017.
Article in English | MEDLINE | ID: mdl-28859143

ABSTRACT

Squamous cell carcinoma of the skin is the second most common cutaneous malignancy. Despite various available treatment methods and advances in noninvasive diagnostic techniques, the incidence of metastatic cutaneous squamous cell carcinoma is rising. Deficiency in effective preventive or treatment methods of transformed keratinocytes leads to necessity of searching for new anticancer agents. The present study aims to evaluate the possibility of using wool hydrolysates as such agents. Commercially available compounds such as 5-fluorouracil, ingenol mebutate, diclofenac sodium salt were also used in this study. The process of wool degradation was based on chemical pre-activation and enzymatic digestion of wool. The effect of mentioned compounds on cell viability of squamous carcinoma cell line and healthy keratinocytes was evaluated. The obtained data show a significantly stronger effect of selected wool hydrolysates compared to commercial compounds (p<0.05) on viability of cells. The wool hydrolysates decreased squamous cell carcinoma cells viability by up to 67% comparing to untreated cells. These results indicate bioactive properties of wool hydrolysates, which affect the viability of squamous carcinoma cells and decrease their number. We hypothesize that these agents may be used topically for treatment of transformed keratinocytes in actinic keratosis and invasive squamous skin cancer in humans.


Subject(s)
Carcinoma, Squamous Cell/drug therapy , Protein Hydrolysates/chemistry , Skin Neoplasms/drug therapy , Wool/chemistry , Animals , Antineoplastic Agents/pharmacology , Carcinoma, Squamous Cell/pathology , Cell Line, Tumor , Cell Survival/drug effects , Diclofenac/pharmacology , Diterpenes/pharmacology , Fluorouracil/pharmacology , Humans , Keratinocytes/drug effects , Keratinocytes/pathology , Protein Hydrolysates/pharmacology , Skin Neoplasms/pathology
3.
ChemMedChem ; 12(19): 1637-1644, 2017 10 09.
Article in English | MEDLINE | ID: mdl-28834399

ABSTRACT

According to the World Health Organization, the mortality rate among patients with pancreatic cancer will increase in the upcoming years. Gemcitabine is the first choice for treatment of pancreatic malignancy, but increasing resistance to this drug is decreasing its overall efficacy. Studies on new therapies that target metabolic pathways, growth factor inhibitors, and tumor stroma or tumor stem cells are currently underway in many research groups. Herein we report the bioactive properties (cytotoxicity and hemolytic activity) of synthetic peptidomimetics containing an opioid tripeptide fragment (Tyr-R1 -R2 -; where R1 is d-Ala or d-Thr, and R2 is Phe or Trp) hybridized with trans-1-cinnamylpiperazine. These compounds are stable in plasma up to 96 h and exhibit low hemotoxicity and good inhibitory effects on cancer cell growth in two- and three-dimensional in vitro models of pancreatic cancer.


Subject(s)
Analgesics, Opioid/chemistry , Analgesics, Opioid/pharmacology , Oligopeptides/chemistry , Oligopeptides/pharmacology , Piperazines/chemistry , Amino Acid Sequence , Analgesics, Opioid/chemical synthesis , Analgesics, Opioid/metabolism , Cell Culture Techniques , Cell Line , Cell Proliferation/drug effects , Cell Survival/drug effects , Erythrocytes/cytology , Erythrocytes/drug effects , Erythrocytes/metabolism , Hemolysis/drug effects , Humans , Isomerism , Models, Biological , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Peptidomimetics , Piperazine , Protein Binding , Receptors, Opioid, mu/genetics , Receptors, Opioid, mu/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...